Guest User August 28, 2023 Corporate Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
Guest User June 21, 2023 Brilacidin Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
Guest User June 5, 2023 Corporate Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
Guest User April 17, 2023 Brilacidin Innovation Pharmaceuticals’ Brilacidin Antifungal Research Published in Nature Communications
Guest User March 15, 2023 Brilacidin Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
Guest User February 23, 2023 Corporate Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
Guest User January 9, 2023 Corporate Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
WKW December 13, 2022 Brilacidin Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis
Guest User November 28, 2022 Corporate Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Guest User November 15, 2022 Brilacidin Scientific Poster on Innovation Pharmaceuticals’ Brilacidin to be Presented at 2022 Chemical and Biological Defense Science & Technology Conference
Guest User October 26, 2022 Corporate NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy “Game-Changing Breakthrough”
Guest User October 4, 2022 Brilacidin Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
Guest User September 15, 2022 Brilacidin New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals’ Brilacidin Presented at 2022 Military Health System Research Symposium
Guest User September 13, 2022 Corporate Innovation Pharmaceuticals’ Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
Guest User August 5, 2022 Brilacidin Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin’s Treatment Potential Against Monkeypox
Guest User July 22, 2022 Brilacidin Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical’s Brilacidin as a Novel Oral Mucositis Drug Candidate
Guest User June 28, 2022 Brilacidin Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
Guest User June 23, 2022 Brilacidin Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
Guest User June 15, 2022 Corporate Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments through a New Image Guided Laser-Based Ablation Technology
Guest User March 15, 2022 Brilacidin, Corporate Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin
